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1. Introduction 
yGlutamy1 transpeptidase catalyzes the initial step 
in the breakdown of glutathione. A proposed role for 
the enzyme in transport processes [ 1,2] is consistent 
with its localization in the plasma membranes of a 
variety of epithelial cells [3,4]. The enzyme is also 
present in human and rat lymphoid cells and the 
activity can be increased by treatment of the cells 
with mitogenic agents [5]. The transpeptidase activity 
of human lymphoblastic lines varies considerably; cell 
lines from patients with lymphoproliferative diseases 
exhibit activities ignificantly lower than lines obtained 
from normal subjects, whereas the highest activity 
was observed in a line derived from a multiple mye- 
loma patient [ 51. 
Ultrastructural localization of the transpeptidase 
activity, results of which are reported here, show that 
the lymphoid cell plasma membrane isthe primary site 
of enzyme activity. A largely uniform distribution of 
enzyme on the cell-surface isindicated from experi- 
ments with ferritin-antibody conjugates. Although 
short-term incubation of cells in cytochemical medi- 
um results in staining of the plasma membrane only, 
longer incubation reveals activity in the membranes 
of the endoplasmic reticulum and the Golgi. This 
intracellular activity may be associated with inter- 
mediate stages in the processing of the enzyme 
en route to its insertion in the plasma membrane and 
may also function in the turnover of intracellular 
glutathione. The similarity of the lymphoid cell 
enzyme to the purified kidney enzyme is evident from 
antibody inhibition studies and gel electrophoresis in 
sodium dodecyl sulfate (SDS). 
* To whom correspondence should be addressed 
2. Materials and methods 
L=y-Glutamyl-p-nitroanilide, glycylglycine, neura- 
minidase and galactose oxidase were purchased from 
Sigma. L-7-Glutamyl(4-methoxy)-2-naphthylamide, 
4aminophthalhydrazide, osmium tetroxide, and ferri- 
tin were obtained from Polysciences. NaB3H4 (100 
mCi/mmol) was from New England Nuclear. Anti- 
bodies against human kidneyy-glutamyl transpeptidase 
(isolated as in [6]) were prepared in rabbits and the 
T-globulin fraction was purified [7]. Conjugation of 
the IgG fraction with ferrltin was done as in [8]. 
Human lymphoid cell lines, RPM1 1788 (from a 
normal subject) and RPM1 8226 (from a patient with 
multiple myeloma), both exhibiting B-cell character- 
istics, were obtained and maintained as in [5]. The 
transpeptidase activities of these lines were 990 and 
11 000 units/mg, respectively (mnol p-nitroaniline 
formed . h-’ . mg protein-’ when assayed as in [5]). 
Labeling of the cell-surface glycoproteins and isola- 
tion of labeled transpeptidase w re done as follows: 
RPM1 8226 cells (“2 X 10’) were washed and sus- 
pended in 1 ml 0.01 M phosphate buffer (pH 7.4) con- 
taining 0.15 M NaCl (phosphate-NaCl). Treatment 
with neuraminidase and galactose oxidase followed 
by labeling with NaB3H4 was done essentially as in 
[9]. In controls, galactose oxidase was omitted. The 
cells were then centrifuged, washed several times with 
phosphate-NaCl, finally suspended in 1 ml buffer 
containing 0.2% Lubrol WX, and homogenized in a 
glass-teflon homogenizer. The homogenate was cen- 
trifuged at 18 000 X g for 60 min; the supematant 
contained all of the cellular transpeptidase activity. 
Purified human kidney transpeptidase (4 Mg/ml) was 
added to the extract and the enzyme was precipitated 
with anti-human kidney transpeptidase IgG. The 
immunoprecipitates were collected by centrifugation, 
ElsevierjNorth-Holland Biomedical Press 273 
Volume 115, number 2 FEBS LETTERS June 1980 
washed thoroughly with phosphate-NaCl buffer con- 
taining Lubrol WX and finally dissolved in 0.1 ml 2% 
SDS. The samples were subjected to electrophoresis 
in 8% polyacrylamide gels in the presence of 0.1% 
SDS, stained with Coomassie blue R-250, destained, 
sliced into 2 mm sections and the slices counted as in 
[91. 
Ultrastructural localization of the transpeptidase 
activity in lymphoid cells was done as in [4,10]. 
Washed cells (-5 X 10’) were mixed with 0.2 ml melted 
agar (2% in phosphate-NaCl) at 45°C. The solidified 
agar block was cut into small pieces and incubated at 
25’C for 60 min in a medium containing y-glutamyl- 
(4-methoxy)-2naphthylamide, Gly-Gly and 4- 
aminophthalhydrazide. In controls, the transpeptidase 
activity was inhibited by the addition of L-serine and 
borate (5 mM each) to the incubation medium [111. 
Osmication, dehydration, and embedding in Araldite 
was done as in [4]. Ultrathin sections were cut on a 
LKB ultramicrotome and observed in a JEM-100B 
electron microscope. 
Lymphoid cells were treated with the ferritin con- 
jugate of anti-human kidney transpeptidase IgG 
as in [4]. Cells were prefuted with 1% formaldehyde 
in phosphate-NaCl for 30 min at 4°C. After washing, 
the cells were incubated with an excess of ferritir- 
IgG conjugate for 2 h at 4°C. In controls, the prefured 
cells were exposed to unconjugated anti-IgG prior to 
the treatment with ferritin-IgG. Excess conjugate 
was removed by washing after which the cells were 
fmed in 2.5% glutaraldehyde in phosphate-NaCl and 
processed for electron microscropy [4]. 
3. Results 
Treatment of intact cells with anti-human kidney 
transpeptidase rum resulted in -70% inhibition of 
the cell transpeptidase activity (fig.1, curve 1). The 
activity of the detergent extract of the cells was sim- 
ilarly inhibited and overnight incubation with the anti- 
serum resulted in complete precipitation of the solu- 
bilized enzyme (fig.1, curve 2). Similar inhibition and 
precipitin curves were obtained when an equivalent 
4 8 12 16 
ANTISERUM (/iI ) 
Fig.1. Effect of human kidney y-glutamyl transpeptidase 
antiserum (rabbit) on the transpeptidase activity of lymphoid 
cells. (1) Human lymphoid cells (-10’ RPM1 8226 cells in 
I ml phosphate-NaCl; 11 000 units enzyme) were treated 
with the antiserum (diluted 1 X 25) for 1 h at 25°C. Aliquots 
(0.2 ml) were taken for enzyme assays. (2) RPM1 8226 cells 
were homogenized with phosphate-NaCl containing 0.2% 
Lubrol WX (1 ml/lo’ cells) and the homogenate centrifuged 
at 18 000 X g for 60 min. The supernatant (1 ml), containing 
all of the cellular enzyme activity, was treated with the 
diluted antiserum asshown. After incubation at 4’C for 24 h, 
the solutions were centrifuged at 5000 X g for 30 min and 
the supernatants assayed for residual activity. Similar lnhibi- 
tion and precipitin curves were obtained with an equivalent 
amount of purified human kidney transpeptidase. The activ- 
ities of human peripheral blood lymphocytes and of cell line 
RPM1 1788 were also inhibited by the antiserum. (3) shows 
the absence of any effect of the antiserum on rat spleen cells 
which had been cultured 72 h after mitogenic stimulation 
with Con A as in [5] (1.2 X 10’ cells/ml phosphate-NaCl; 
3800 units enzyme activity). 
Fig.2. Ultrastructural localization of r-glutamyl transpeptidase in lymphoid cells. (A-E) Cytochemical ocalization of enzyme 
activity in human cell line, RPM1 8226. Note the thicker and darker appearance of the plasma membrane, PM, in (A) indicative 
of transpeptidase activity as compared to the appearance of PM in the control_(C) in which the activity was inhibited. Activity 
was also seen ln the membranes of the endoplasmic reticulum, ER (B) and the Golgi, G (D). (E) is the control for (D). (A-C) X 
50 000; (D-E) X 30 000. (F-I) Treatment of human cell lines RPM1 8226 (F,G) and RPM1 1788 (H,I) with the ferritin conjugate 
of anti-transpeptidase IgG. Note the uniform binding of the conjugate to the outer surface of the plasma membrane of RPM1 
8226 (F) and RPM1 1788 (H). (G,I) are the corresponding controls in which the cells were treated with the IgG prior to addition 
of the ferritin conjugate. 
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amount of purified human kidney transpeptidase was 
used (not shown). Further similarity between the 
lymphoid cell plasma membrane and the kidney 
enzymes was shown when the immunoprecipitate con- 
taining the tritiated enzyme from RPM1 8226 (labeled 
as in section 2; 2500 cpm/lO 000 units) and the 
human kidney enzyme was subjected to SDS-poly- 
acrylamide gel electrophoresis. Results of this experi- 
ment indicated that, like the kidney enzyme [6], the 
lymphoid cell enzyme is also composed of two glyco- 
protein subunits (mol. wt -62 000 and 22 000, res- 
pectively) since radioactivity was found to co-migrate 
with the subunits of kidney enzyme. The heavy sub- 
unit region contained -3-times as much radioactivity 
as the light subunit area. 
Ultrastructural localization studies howed that 
transpeptidase activity in the celI line RPM1 8226 is 
seen in the plasma membranes as indicated by thicker 
and darker appearance of these membranes (fig.2A) 
(due to deposition of the lipophobic, osmiophilic 
reaction product at the site of enzyme activity) as 
compared to the appearance of these membranes in
the corresponding control (fig.2C). Longer incubation 
(2 h) of the cells with the cytochemical medium 
revealed enzyme activity in the membranes of the 
endoplasmic reticulum (fig.2B) and the Golgi (fig.2D). 
Similar localization of transpeptidase activity was 
seen in the cell line REM1 1788 and in Con A-stimu- 
lated rat spleen cells (not shown). No activity :~as 
seen in mitochondria nd nuclei. 
Treatment of prefured cells (REM1 8226 and RPM1 
1788) with anti-transpeptidase IgG-ferritin conjugate 
showed uniform binding of the conjugate to the 
plasma membranes (iig.2F and 2H, respectively). The 
greater labeling seen in the cell line REM1 8226 as 
compared to that in RPM1 1788 is consistent with the 
higher transpeptidase activity in the former cell line. 
Since the ferritin conjugate does not permeate the 
cell membrane, intracellular membranes were not 
labeled under these conditions. 
4. Discussion 
Ultrastructural localization of y-glutamyl trans- 
peptidase activity and antibody inhibition studies 
demonstrate hat the lymphoid cell plasma membrane 
is the primary site of the enzyme in these cells. Reac- 
tion with ferritin-antibody conjugate shows that the 
enzyme is uniformly distributed over the external sur- 
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face of the plasma membrane. Extended incubation 
of the cells in the cytochemical medium revealed 
activity on the membranes of the endoplasmic retic- 
ulum and the Golgi. The cytochemical method permits 
qualitative assessment regarding the relative activities 
in the intracellular and plasma membranes and is in 
accord with studies using impermeable substrate to 
compare the activities of intact cells and cell sonicates 
which showed that most of the cellular activity is 
indeed present on the celI surface [5]. Whether the 
enzyme on the intracellular membranes merely repre- 
sents intermediate stages in the processing of this 
plasma membrane nzyme, shown to be a glycopro- 
tein, or may in fact be significant in utilization of 
intracellular glutathione remairs to be evaluated. The 
plasma membrane enzyme is similar in several respects 
to the purified kidney enzyme. 
Intracellular glutathione can be translocated out 
of the lymphoid cells [2,12]. Localization of the 
major transpeptidase activity on the lymphoid cell 
surface suggests hat the enzyme can interact with 
glutathione that is translocated to the cell surface as 
well as extracellular (plasma) glutathione. Also, the 
ease with which the enzyme can be localized and 
assayed, and the marked variation in the activity of 
cells derived from patients with various neoplastic 
diseases, may serve to make this enzyme a useful 
marker in studies relating to differentiation and neo- 
plasia [S]. 
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